Augmenix Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Augmenix's estimated annual revenue is currently $32.9M per year.
- Augmenix's estimated revenue per employee is $251,000
- Augmenix has 131 Employees.
- Augmenix grew their employee count by 3% last year.
- Augmenix currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
What Is Augmenix?
Augmenix, Inc. is a privately held medical device company focused on the development and commercialization of radiation oncology and urology products using its proprietary hydrogel technology. The company is using this technology to develop products that decrease unintended radiation damage to normal organs during cancer radiation therapy and to mark soft tissue. The SpaceOAR System (OAR stands for organ at risk) is an absorbable hydrogel that temporarily moves the rectum away from the prostate and the high intensity radiation zone, protecting the rectum in men undergoing radiation therapy for prostate cancer. Clinically proven, the created space reduces rectal radiation injury and the resulting long term complications. It is the first and only prostate cancer spacing device to receive Food and Drug Administration (FDA) clearance. Additionally, Augmenix has developed an absorbable tissue marker that marks soft tissue for a surgical procedure or future surgical procedures. TraceIT Tissue Marker is visible on multi-modality imaging allowing for improved tissue marking. This technology, licensed from Incept, LLC, comes from a line of products that have made a meaningful impact in the areas of neurosurgery and interventional cardiology. Augmenix is bringing this technology to the field of radiation oncology through high quality investors and an experienced management team. Augmenix, SpaceOAR, and SpaceOAR logo are registered trademarks of Augmenix, Inc.keywords:N/A
Number of Employees
Employee Growth %
Boston Scientific closes $600m Augmenix buyout ... based Augmenix, announced in September, called for $500 million in up-front cash and ...
Boston Scientific (NYSE:BSX) said yesterday that it put $600 million on the table for Augmenix and its SpaceOar device. The deal for Bedford, ...
Boston Scientific Corp., a medical device company with major operations in the Twin Cities, closed on a $4.3 billion acquisition of British health ...